Author:
Abraham Jacob Linu,Gupta Animesh
Abstract
DLBCL is the most common type of NHL diagnosed in the world. It is a highly heterogeneous disease with variable prognosis and is generally managed with standard chemo-immunotherapy and its variations. Immunohistochemistry has been found to be useful method to both sub-classify and to predict prognosis of this disease. IHC utilises various CD markers like CD10, BCL2 and IRF4 to divide DLBCL into GCB and non-GCB subtype. In clinical trials, GCB subtype has been shown to have a better prognosis and a response to treatment when compared to non-GCB subtype. Double hit/double expressor is a newer variant of DLBCL that stains positive for MYC and BCL2 or BCL6 and has been found to do better with more aggressive forms of therapy. Significance of various other CD markers is still largely unknown and further research is required in this area to better elucidate their clinical application.